About GelMEDIX
GelMEDIX is a company based in Newton (United States) founded in 2019. GelMEDIX has raised $20.84 million across 5 funding rounds from investors including Safar Partners, HTL Biotechnology and Beacon Angels. GelMEDIX offers products and services including Ocular Cell Therapy Formulations. GelMEDIX operates in a competitive market with competitors including Annexon, Aldeyra, Nicox, Gyroscope and MeiraGTx, among others.
- Headquarter Newton, United States
-
Sectors
Healthcare
-
Email
Locked
-
Phone
Locked
-
Website
Locked
- Legal Name Gelmedix, Inc.
-
Annual Revenue
Not available
-
Net Profit
Not available
-
EBITDA
Not available
-
Total Equity Funding
$20.84 M (USD)
in 5 rounds
-
Latest Funding Round
$13 M (USD), Seed
Feb 17, 2026
-
Investors
Safar Partners
& 4 more
-
Employee Count
Not available
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Products & Services of GelMEDIX
GelMEDIX offers a comprehensive portfolio of products and services, including Ocular Cell Therapy Formulations.
Engineered to boost cell viability and aid vision regeneration
People of GelMEDIX
Unlock access to complete
Unlock access to complete
Funding Insights of GelMEDIX
GelMEDIX has successfully raised a total of $20.84M across 5 strategic funding rounds. The most recent funding activity was a Seed round of $13 million completed in February 2026. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
Investors in GelMEDIX
GelMEDIX has secured backing from 5 investors, including venture fund and institutional investors. Prominent investors backing the company include Safar Partners, HTL Biotechnology and Beacon Angels.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
-
|
Locked | Locked | Locked | |
|
-
|
Locked | Locked | Locked | |
|
-
|
Locked | Locked | Locked |
Investor details for GelMEDIX
Investor domains, locations, round participation, and complete history require an active premium plan.
- Investor domains
- Investor locations
- Funding rounds
- Participation history
Verified entity values are shown only after access is granted.
Investments & Acquisitions by GelMEDIX
Investment portfolio details for GelMEDIX
Portfolio company identities, transaction dates, round details, and investment values require an active premium plan.
- Portfolio identities
- Transaction dates
- Round details
- Investment values
Verified entity values are shown only after access is granted.
Financial Statements - GelMEDIX
Detailed financials for GelMEDIX
Historical revenue, profit, statement rows, ratios, and trend charts require an active premium plan.
- Historical revenue
- Profit trends
- Statement rows
- Financial ratios
Verified entity values are shown only after access is granted.
Gelmedix Comparisons
Peer comparison for GelMEDIX
Named peer metrics, headcount, funding, location, and side-by-side benchmarks require an active premium plan.
- Named peers
- Headcount comparison
- Funding comparison
- Operating benchmarks
Verified entity values are shown only after access is granted.
Competitors of GelMEDIX
GelMEDIX operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Annexon, Aldeyra, Nicox, Gyroscope and MeiraGTx, among others.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| Locked | Locked | Locked |
Developer of antibodies to treat complement-mediated neurodegenerative diseases
|
|
| Locked | Locked | Locked |
Drug candidates for immune-mediated diseases are developed by Aldeyra.
|
|
| Locked | Locked | Locked |
Nitric oxide-based therapeutics for glaucoma and eye conditions are developed.
|
|
| Locked | Locked | Locked |
Mobile SDK developed for app engagement and monetization strategies.
|
|
| Locked | Locked | Locked |
Gene therapies for ocular and neurodegenerative diseases are developed.
|
|
| Locked | Locked | Locked |
Viral vector-based gene therapies for retinal diseases are developed.
|
Detailed competitors of GelMEDIX
Competitor domains, locations, full profiles, and operating metrics require an active premium plan.
- Domains and locations
- Full company profiles
- Operating metrics
- Competitive positioning
Verified entity values are shown only after access is granted.
Latest news on Gelmedix
Complete news archive for GelMEDIX
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about GelMEDIX
GelMEDIX was founded in 2019 and raised its 1st funding round 3 years after it was founded.
GelMEDIX is headquartered in Newton, United States. It is registered at Newton, Massachusetts, United States.
GelMEDIX is a funded company, having raised a total of $20.84M across 5 funding rounds to date.
GelMEDIX was founded in 2019 in Newton, United States, within the biotechnology sector. Focus is placed on the development of hydrogel-based platforms for drug delivery in ophthalmic applications. Operations center on research and innovation to create sustained-release systems for eye treatments. The technology targets conditions requiring localized and prolonged medication administration, with activities conducted from the companys base in the United States.
GelMEDIX's top competitors include Annexon, Alimera Sciences and MeiraGTx.
GelMEDIX offers Ocular Cell Therapy Formulations.
GelMEDIX has 5 investors. Key investors include Safar Partners, HTL Biotechnology, Beacon Angels, TiE Boston, and Boston Harbor Angels.